source
- FDA advisory panel backs Replimune’s melanoma immunotherapy combined with OpdivoThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10-3 to recommend Replimune’s RP1 immunotherapy, used together with Bristol Myers Squibb’s Opdivo, for patients with advanced…
- BD recalls specific lots of intraosseous needle sets over obturator removal issuesBD announced a voluntary recall of certain lots of its intraosseous vascular access system needle sets after users reported difficulty removing the obturator after placement. The issue is linked t…